Core Viewpoint - Company is enhancing its investment in AI pharmaceutical sector through a capital increase in its wholly-owned subsidiary, Lingqing Smart Pharmaceutical Technology Co., Ltd. [2][3] Group 1: Capital Increase Details - Company announced a capital increase of 450 million yuan to Lingqing Smart, raising its registered capital from 50 million yuan to 500 million yuan [3] - The capital increase aims to strengthen the subsidiary's financial capabilities and support its future research and business expansion [2][3] Group 2: Strategic Importance of AI in Pharmaceuticals - AI is becoming a crucial technology for improving the efficiency and cost-effectiveness of innovative drug development [3] - Lingqing Smart is positioned as the core entity for the company's AI pharmaceutical initiatives, currently in the phase of building its business and talent framework [3] Group 3: Future Plans and Collaborations - Company plans to establish an AI Pharmaceutical Committee and has already invested in Kema Biotechnology through Lingqing Smart [4] - Lingqing Smart acquired a 9.53% stake in Kema Biotechnology, which focuses on antibody design using generative AI models [4]
华兰股份拟4.5亿元增资灵擎数智